Literature DB >> 8845446

Clinical significance of drug resistance in human immunodeficiency virus.

D D Richman1.   

Abstract

Antiretroviral drugs exert only limited activity against viruses that replicate persistently to high levels. Thus, drug-resistant viruses readily emerge. It has been difficult to assess the contribution of such drug resistance to the failure of treatment with drugs that have only limited effectiveness in the first place. The emergence of zidovudine-resistant human immunodeficiency virus is predictive of clinical disease progression, although the relationship of this event to treatment failure is particularly complicated. The relationship between drug resistance and the loss of activity of non-nucleoside reverse transcriptase inhibitors and protease inhibitors appears to be more straightforward. The optimal use of antiretroviral drugs and combination regimens requires an appreciation of the impact of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8845446     DOI: 10.1093/clinids/21.supplement_2.s166

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Susceptibilities of simian immunodeficiency virus to protease inhibitors.

Authors:  Angelica C Giuffre; Joanne Higgins; Robert W Buckheit; Thomas W North
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1.

Authors:  K Leriche-Guérin; M A Trabaud; L Cotte; F Bissuel; E Deruelle; P Rougier; C Trépo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

3.  A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques.

Authors:  K K Van Rompay; J L Greenier; M L Marthas; M G Otsyula; R P Tarara; C J Miller; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.

Authors:  Koen K A Van Rompay; Tim B Matthews; Joanne Higgins; Don R Canfield; Ross P Tarara; Mark A Wainberg; Raymond F Schinazi; Niels C Pedersen; Thomas W North
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 5.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.